CN104254532A - 磷酸肌醇3-激酶抑制剂 - Google Patents

磷酸肌醇3-激酶抑制剂 Download PDF

Info

Publication number
CN104254532A
CN104254532A CN201380013216.5A CN201380013216A CN104254532A CN 104254532 A CN104254532 A CN 104254532A CN 201380013216 A CN201380013216 A CN 201380013216A CN 104254532 A CN104254532 A CN 104254532A
Authority
CN
China
Prior art keywords
compound
alkyl
independently
optionally substituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380013216.5A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬·约瑟夫·沙特勒沃斯
弗兰克·亚历山德勒·希尔瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karus Therapeutics Ltd
Original Assignee
Karus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karus Therapeutics Ltd filed Critical Karus Therapeutics Ltd
Publication of CN104254532A publication Critical patent/CN104254532A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380013216.5A 2012-03-08 2013-03-08 磷酸肌醇3-激酶抑制剂 Pending CN104254532A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1204125.7A GB201204125D0 (en) 2012-03-08 2012-03-08 Compounds
GB1204125.7 2012-03-08
PCT/GB2013/050583 WO2013132270A1 (en) 2012-03-08 2013-03-08 Phosphoinositide 3-kinase inhibitors

Publications (1)

Publication Number Publication Date
CN104254532A true CN104254532A (zh) 2014-12-31

Family

ID=46026238

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380013216.5A Pending CN104254532A (zh) 2012-03-08 2013-03-08 磷酸肌醇3-激酶抑制剂

Country Status (6)

Country Link
US (2) US9663487B2 (enExample)
EP (1) EP2822943B1 (enExample)
CN (1) CN104254532A (enExample)
GB (1) GB201204125D0 (enExample)
IN (1) IN2014DN07509A (enExample)
WO (1) WO2013132270A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135855A (zh) * 2015-08-19 2018-06-08 卡鲁斯治疗有限公司 包含三环杂环化合物的组合物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5746172B2 (ja) 2009-08-20 2015-07-08 カルス セラピューティクス リミテッド ホスホイノシチド３−キナーゼ阻害剤としての三環式複素環化合物
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
AU2013343291B2 (en) 2012-11-07 2018-05-10 Karus Therapeutics Ltd Novel histone deacetylase inhibitors and their use in therapy
US9737521B2 (en) 2012-11-08 2017-08-22 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
EP2994465B1 (en) 2013-05-10 2018-08-15 Karus Therapeutics Limited Novel histone deacetylase inhibitors
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
AR117398A1 (es) 2018-03-12 2021-08-04 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa 2
GB201909468D0 (en) 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002551A1 (en) * 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
CN101228161A (zh) * 2005-05-20 2008-07-23 沃泰克斯药物股份有限公司 适用作蛋白激酶抑制剂的吡咯并吡啶类
WO2008145688A2 (en) * 2007-06-01 2008-12-04 Glaxo Group Limited Pyrrolopyridine compounds, process for their preparation, and their use as medicaments
CN101663276A (zh) * 2007-01-31 2010-03-03 沃泰克斯药物股份有限公司 用作激酶抑制剂的2-氨基吡啶衍生物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445742A1 (de) 1963-11-06 1968-12-19 Bayer Ag Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
US4017500A (en) 1973-07-16 1977-04-12 Schering Corporation Certain 8-amino-1,7-naphthyridines
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
CN100345830C (zh) 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN1922171B (zh) 2004-02-26 2012-10-17 Aska制药株式会社 嘧啶衍生物
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
US20070208053A1 (en) * 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
MX2008013583A (es) 2006-04-26 2008-10-31 Genentech Inc Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen.
US8252792B2 (en) 2006-04-26 2012-08-28 F. Hoffman-La Roche Ag Pyrimidine derivatives as PI3K inhibitors
SG178786A1 (en) 2006-11-13 2012-03-29 Lilly Co Eli Thienopyrimidinones for treatment of inflammatory disorders and cancers
JP2010518014A (ja) 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用な２−アミノピリジン誘導体
US20100063032A1 (en) 2007-03-28 2010-03-11 Debenham John S Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators
WO2008150827A1 (en) 2007-05-29 2008-12-11 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
EP2324022A1 (de) 2008-08-05 2011-05-25 Boehringer Ingelheim International GmbH Substituierte naphthyridine und ihre verwendung als arzneimittel
WO2010037765A2 (en) 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2011012883A1 (en) 2009-07-29 2011-02-03 Karus Therapeutics Limited Benzo [e] [1, 3 ] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
JP5746172B2 (ja) 2009-08-20 2015-07-08 カルス セラピューティクス リミテッド ホスホイノシチド３−キナーゼ阻害剤としての三環式複素環化合物
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
EP2736895B1 (en) 2011-07-27 2016-01-06 Astrazeneca AB 2-(2,4,5-substituted-anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
WO2014081718A1 (en) 2012-11-20 2014-05-30 Genentech, Inc. Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
EP2994465B1 (en) 2013-05-10 2018-08-15 Karus Therapeutics Limited Novel histone deacetylase inhibitors
WO2014210354A1 (en) 2013-06-28 2014-12-31 Genentech, Inc. Azaindazole compounds as inhibitors of t790m containing egfr mutants
US20150105383A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002551A1 (en) * 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
CN101228161A (zh) * 2005-05-20 2008-07-23 沃泰克斯药物股份有限公司 适用作蛋白激酶抑制剂的吡咯并吡啶类
CN101663276A (zh) * 2007-01-31 2010-03-03 沃泰克斯药物股份有限公司 用作激酶抑制剂的2-氨基吡啶衍生物
WO2008145688A2 (en) * 2007-06-01 2008-12-04 Glaxo Group Limited Pyrrolopyridine compounds, process for their preparation, and their use as medicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOHAMMAD SAIFUDDIN ET AL.: "Water-Accelerated Cationic π-(7-endo) Cyclisation:Application to Indole-Based Peri-Annulated Polyheterocycles", 《EUR.J.ORG.CHEM.》, no. 26, 20 July 2010 (2010-07-20), pages 5109 - 3 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135855A (zh) * 2015-08-19 2018-06-08 卡鲁斯治疗有限公司 包含三环杂环化合物的组合物

Also Published As

Publication number Publication date
IN2014DN07509A (enExample) 2015-04-24
US9663487B2 (en) 2017-05-30
EP2822943B1 (en) 2018-10-03
GB201204125D0 (en) 2012-04-25
US10035785B2 (en) 2018-07-31
US20180072699A1 (en) 2018-03-15
WO2013132270A1 (en) 2013-09-12
US20150080395A1 (en) 2015-03-19
EP2822943A1 (en) 2015-01-14

Similar Documents

Publication Publication Date Title
CN104254532A (zh) 磷酸肌醇3-激酶抑制剂
JP5746172B2 (ja) ホスホイノシチド３−キナーゼ阻害剤としての三環式複素環化合物
EP2563788B1 (en) Naphthridine derivatives as pi3k inhibitors for the treatment of cancer and immune-inflammatory diseases
JP6516371B2 (ja) ホスホイノシチド３−キナーゼ阻害剤としての三環式複素環式化合物
US8981087B2 (en) Benzo [E] [1,3] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
JP3649395B2 (ja) 縮合ヘテロアリール誘導体
CN110809472A (zh) 用于制备苯二氮*衍生物的方法
US10442815B2 (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
CN108137613B (zh) 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物
JP2021519308A (ja) 転写活性化タンパク質のイミダゾピペラジン阻害剤
ES2641948T3 (es) Derivados de benzo[e][1,3]oxazin-4-ona como inhibidores de fosfoinositida-3-quinasa

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141231

WD01 Invention patent application deemed withdrawn after publication